RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

@article{Loi2016RASMAPKAI,
  title={RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.},
  author={Sherene Loi and Sathana Dushyanthen and Paul A. Beavis and Roberto Salgado and Carsten Denkert and Peter Savas and Susan E. Combs and David L. Rimm and Jennifer M Giltnane and M Valeria Estrada and Violeta Sanchez and Melinda E Sanders and Rebecca S. Cook and Mark A Pilkinton and Simon A Mallal and Kai Yuen Wang and Vincent A. Miller and Phil J. Stephens and Roman Yelensky and Franco D. Doimi and Henry Leonidas G{\'o}mez and Sergey V Ryzhov and Phillip K Darcy and Carlos L. Arteaga and Justin M Balko},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2016},
  volume={22 6},
  pages={1499-509}
}
PURPOSE Tumor-infiltrating lymphocytes (TIL) in the residual disease (RD) of triple-negative breast cancers (TNBC) after neoadjuvant chemotherapy (NAC) are associated with improved survival, but insight into tumor cell-autonomous molecular pathways affecting these features are lacking. EXPERIMENTAL DESIGN We analyzed TILs in the RD of clinically and molecularly characterized TNBCs after NAC and explored therapeutic strategies targeting combinations of MEK inhibitors with PD-1/PD-L1-targeted… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 7 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

Breast Cancer Immunotherapy: Facts and Hopes.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2018
View 9 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 39 references

A phase Ib study of pembrolizumab ( MK - 3475 ) in patients with advanced triple - negative breast cancer

R Nanda, LQ Chow, +3 authors R Geva
Cancer Res • 2015

A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer [abstract

R Nanda, LQ Chow, +3 authors R Geva
Cancer Res • 2015
View 1 Excerpt

Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Presented at the American Association for Cancer Research Annual Meeting

LA Emens, FS Braiteh, P Cassier, a. et
Philadelphia Abstract • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…